Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)
NCT ID: NCT01701479
Last Updated: 2020-07-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
288 participants
INTERVENTIONAL
2012-01-31
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
NCT01592045
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
NCT00026312
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
NCT01711554
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
NCT01175356
Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma
NCT01334515
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Ch14.18/CHO has been shown to improve the outcome of patients with neuroblastoma. However, one of the side effects of receiving ch14.18/CHO is severe pain. High doses of intravenous morphine are needed to control the pain and this means that patients must stay in hospital. Results from other clinical trials have shown that giving ch14.18/CHO over a longer time reduces pain, yet the drug still works just as well to fight the neuroblastoma. The clinical trial aims to give ch14.18/CHO over a longer time so that intravenous morphine is not needed and that this treatment regimen can ultimately be given in an outpatient setting.
Ch14.18/CHO is a monoclonal antibody. Monoclonal antibodies are made in the laboratory and are designed to bind to specific cancer cells. Ch14.18/CHO was designed to bind to neuroblastoma cells and other cancer cells that express the GD-2 antigen. The GD-2 antigen is expressed by virtually all neuroblastoma cells. An antigen is a substance that stimulates an immune response in the body by producing antibodies. Thus, when ch14.18/CHO binds to the neuroblastoma cells, the body's immune system is stimulated to attack and kill the neuroblastoma cells. Ch14.18/CHO is called chimeric, because it was genetically engineered to consist of 30% mouse-protein and of 70% human protein.
Ch14.18/CHO represents a new kind of cancer therapy that, unlike chemotherapy and radiation, targets the destruction of cancer cells without destroying nearby healthy cells. There is laboratory evidence to suggest that ch14.18/CHO can activate the body's own immune cells to destroy cancer cells. These immune cells include killer cells that are activated or stimulated by aldesleukin (IL-2). Therefore this treatment is a combination of ch14.18/CHO and aldesleukin (IL-2).
Aldesleukin (IL-2) is a substance that is similar to a substance made by the body in all individuals. Under normal circumstances, the body makes small amounts of aldesleukin (IL-2) that help white blood cells fight infection. It is now possible to make aldesleukin (IL-2) in the laboratory and give humans much higher doses than their own body makes. There is evidence in the laboratory and in animals that aldesleukin (IL-2) increases the anti-cancer effect of monoclonal antibodies like ch14.18/CHO. We wish to study whether aldesleukin (IL-2) can help improve the effectiveness of ch14.18/CHO in humans.
In addition to ch14.18/CHO and aldesleukin (IL-2), isotretinoin (13-cis-RA) will also be given. Isotretinoin (13-cis-RA) is considered standard treatment for patients with neuroblastoma and works by induction of neuroblastoma cell death.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental arm
Subcutaneous aldesleukin (IL-2) will be given at a dose of 6 x 106 IU/m2/day in two 5 day blocks (days 1-5 and 8-12).
A continuous infusion of ch14.18/CHO is started on day 8. The duration of the infusion is dependent on the assigned infusion schedule. The duration will range from 10 to 21 days. Three dose levels will be considered with respect to daily dose (7 mg/m2, 10 mg/m2, 15 mg/m2), which relates to total doses of 100 mg/m2,150 mg/m2 and 210 mg/m2.
Patients will receive isotretinoin (13-cis-RA) 160 mg/m²/day divided into two equal doses given orally twice a day for 14 days after the completion of the ch14.18/CHO infusion. The starting day is dependent on the duration of ch14.18/CHO infusion and may be either day 19, 23, 24 or 30.
ch14.18/CHO
Aldesleukin
Isotretinoin
Comparator arm
A continuous infusion of ch14.18/CHO is started on day 8. The duration of the infusion is dependent on the assigned infusion schedule. The duration will range from 10 to 21 days. Three dose levels will be considered with respect to daily dose (7 mg/m2, 10 mg/m2, 15 mg/m2), which relates to total doses of 100 mg/m2,150 mg/m2 and 210 mg/m2.
Patients will receive isotretinoin (13-cis-RA) 160 mg/m²/day divided into two equal doses given orally twice a day for 14 days after the completion of the ch14.18/CHO infusion. The starting day is dependent on the duration of ch14.18/CHO infusion and may be either day 19, 23, 24 or 30.
ch14.18/CHO
Isotretinoin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ch14.18/CHO
Aldesleukin
Isotretinoin
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must be diagnosed with neuroblastoma according to the INSS criteria.
* Must have received at least one previous high dose treatment followed by stem cell rescue after conventional therapy.
* Must fulfil one of the following criteria:
* Patients with stage 4 neuroblastoma on the current high-risk SIOPEN trial (HR-NBL-1/SIOPEN) either with primary refractory disease having had more than two front-line treatments or patients ineligible for the R2 randomization due to major delays after completed high-dose treatments.
* Treated and responding relapse after primary stage 4 disease, without signs of progression at study entry
* Treated and responding disseminated relapse after primary localized neuroblastoma without signs of progression at study entry.
* Patients must have a performance status greater or equal 70% (Lansky Score or Karnofsky, see Appendix 1: performance Scales , page 91)
* Patients must have an estimated life expectancy of at least 12 weeks.
* Patients must consent to the placement of a central venous line, if one has not already been placed.
* Patients must be off any standard or experimental treatments for at least two weeks prior to study entry and be fully recovered from the short term major toxic effects.
* Patients must have no immediate requirements for palliative chemotherapy, radiotherapy or surgery.
* At least 4 weeks after major surgery (e.g. laporotomy or thoracotomy) and fully recovered from any post-surgical complications.
* HIV and Hepatitis B negative.
* Females of childbearing potential must have a negative pregnancy test. Patients of childbearing potential must agree to use an effective birth control method. Female patients who are lactating must agree to stop breast-feeding.
* Patients may have had prior CNS metastasis providing the following criteria are all met:
* the patient's CNS disease has been previously treated,
* the patient's CNS disease has been clinically stable for four weeks prior to starting this study (assessment must be made clinically and by CT or MRI scan),
* the patient is off steroids for CNS disease for four weeks prior to starting on study and during the course of the study.
* Patients with seizure disorders may be enrolled if on anticonvulsants and are well controlled.
* All patients and/or their parents or legal guardians must sign a written informed consent
* All institutional and national requirements for human studies must be met.
* Laboratory Testing:
* Patients should have a shortening fraction of \>= 30 % by Echocardiogram.
* Patients should have FEV1 and FVC \>60% of the predicted by pulmonary function tests. Children unable to do PFTs should have no dyspnea at rest and a pulse oximetry \>94% on room air.
* All patients must have adequate bone marrow function as defined by ANC \>1 10\^9/L, platelets \>= 50 10\^9/L and haemoglobin \> 9.0 g/dL.
* Patients must have adequate liver function, as defined by an ALT or AST \< 5 x normal and a total bilirubin \< 1.0 mg/dL.
* Patients must have adequate renal function, as defined by a serum creatinine \<1.5 mg/dL or a creatinine clearance or radioisotope GFR of \> 60 mL/minute/1.73m2.
Exclusion Criteria
* Patients who have previously received treatment with ch14.18/SP2/0 and/or ch14.18/CHO.
* Platelet transfusion dependent.
* Patients with significant intercurrent illnesses and/or any of the following:
* Patients with symptoms of congestive heart failure or uncontrolled cardiac rhythm disturbance.
* Patients with significant psychiatric disabilities or uncontrolled seizure disorders.
* Patients with active infections.
* Patients with a clinically significant neurologic deficit or objective peripheral neuropathy (Grade \>2) are ineligible.
* Patients with clinically significant, symptomatic, pleural effusions.
* Patients who require, or are likely to require, corticosteroid or other immunosuppressive drugs.
* Concurrent treatment with any non-trial anticancer therapies.
1 Year
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Medicine Greifswald
OTHER
St. Anna Children's Hospital, Vienna
UNKNOWN
Hospital Universitario La Fe
OTHER
Istituto Giannina Gaslini
OTHER
Gustave Roussy, Cancer Campus, Grand Paris
OTHER
Schneider Children's Medical Center, Israel
OTHER
Great Ormond Street Hospital for Children NHS Foundation Trust
OTHER
University Hospital, Toulouse
OTHER
Johann Wolfgang Goethe University Hospital
OTHER
Jena University Hospital
OTHER
Children's University Hospital, Ireland
OTHER
University Hospital Tuebingen
OTHER
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
OTHER
Alder Hey Children's NHS Foundation Trust
OTHER
University Hospitals Bristol and Weston NHS Foundation Trust
OTHER
Newcastle-upon-Tyne Hospitals NHS Trust
OTHER
The Leeds Teaching Hospitals NHS Trust
OTHER
NHS Greater Glasgow and Clyde
OTHER
Medical University of Graz
OTHER
Medical University Innsbruck
OTHER
Centre Leon Berard
OTHER
Hospital Infantil Universitario Niño Jesús, Madrid, Spain
OTHER
University Hospital Southampton NHS Foundation Trust
OTHER
Institut Curie
OTHER
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
OTHER
St. Anna Kinderkrebsforschung
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Holger Lode, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University Medicine Greifswald
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St. Anna Kinderspital
Vienna, , Austria
Institut Curie
Paris, , France
Institut Gustave Roussy
Villejuif, , France
University Children's Hospital
Greifswald, , Germany
Schneider Children's Medical Centre of Israel
Petach Tikvah, , Israel
Gaslini Children's Hospital
Genova, , Italy
Hospital Universitario La Fe
Valencia, , Spain
Birmingham Children's Hospital NHS Foundation Trust
Birmingham, , United Kingdom
University Hospitals Bristol NHS Foundation Trust
Bristol, , United Kingdom
Leeds Teaching Hospitals NHS Trust
Leeds, , United Kingdom
Alder Hey Children's NHS Foundation Trust
Liverpool, , United Kingdom
University College Hospitals NHS Foundation Trust
London, , United Kingdom
Great Ormond Street Hospital for Children NHS Foundation Trust
London, , United Kingdom
The Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-018077-31
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
012010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.